Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

11,350articles mentioning institutions

22,378institution mentions

9,137distinct institutions extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted institutions

Showing 1,621–1,680 of 9,137, ordered by supporting articles. Choose a institution to see its evidence.

Uganda Heart Institute2 Uganda National Council for Science and Technology2 Unit2 United Kingdom Prospective Diabetes Study2 Unity Health Toronto2 Unity Health Toronto Research Ethics Board2 Universitair Ziekenhuis Brussel2 University Children’s Hospital in Belgrade2 University Clinical Center of Serbia2 University Hospital Coventry and Warwickshire2 University Hospital Essen2 University Hospital Galway2 University Hospital Zurich2 University Hospital of Modena2 University Hospital of North Norway2 University Hospitals Coventry and Warwickshire NHS Trust2 University Hospitals Sussex2 University Hospitals of North Midlands2 University Malaya Medical Centre2 University Medical Centre Utrecht2 University of Adelaide2 University of Amsterdam2 University of Athens2 University of Bonn2 University of Bristol2 University of Freiburg2 University of Galway2 University of Ghana2 University of Houston2 University of Lagos2 University of Leipzig2 University of Malaya Medical Centre2 University of Nairobi2 University of North Carolina2 University of North Carolina at Chapel Hill2 University of Nottingham2 University of Otago2 University of Ottawa2 University of Pretoria2 University of Queensland HREC2 University of Queensland Human Research Ethics Committee2 University of Regensburg2 University of Southampton2 University of Southern California2 University of Surrey2 University of Texas Health Science Center at Houston2 University of Toronto Health Sciences Research Ethics Board2 University of Utah Office of Comparative Medicine2 University of Washington Institutional Review Board2 University of Zambia2 University of the Witwatersrand2 Université du Québec à Rimouski2 Upper Gastrointestinal Cancer Early Detection Program2 Ural Children Eye Study2 Ural Eye and Medical Study2 Ural Very Old Study2 Valve Academic Research Consortium2 Vancouver General Hospital2 Vanderbilt University2 Vector Laboratories2

View all 9,137 institutions on one page

Articles mentioning institutions

11,350 articles · page 168 of 946

455 Treg-associated ICOS as a possible biomarker for PD-1 therapy resistance in melanoma patients

jitc · abstract · 2025-11-04 · 3 matching annotations

95.7%

University of California Irvine Chao Family Comprehensive Cancer Center melanoma nivolumab ipilimumab PD-1 immunotherapy αPD-1

… the Institutional Animal Care and Use Committee (IACUC) of the University of California Irvine; approval number AUP22-092 and with a pending IRB.Abstract 455 …

461 Circadian control of the tumor immune microenvironment determines immune checkpoint inhibitor efficacy

jitc · abstract · 2025-11-04 · 3 matching annotations

92.5%

UT Southwestern Medical Center N Engl J Med ipilimumab Nivolumab sunitinib nab-paclitaxel Atezolizumab CTLA-4

…the Institutional Animal Care and Use Committees (IACUC) of the UT Southwestern Medical Center. Clinical samples and data were collected as part of a prospect…

474 Disabling PSGL-1 abrogates immune suppression and resistance to PD-1 blockade in pancreatic cancer

jitc · abstract · 2025-11-04 · 3 matching annotations

89.2%

Sanford Burnham Prebys Sidney Kimmel NCI-Designated Comprehensive Cancer Center Pancreatic ductal adenocarcinoma (PDAC)Cytek Aurora

…32325 for the Cytek Aurora housed in the Flow Cytometry Core at Sanford Burnham Prebys.References Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy…

492 Phase 2 single-arm study of trans-arterial tirapazamine embolization (TATE) plus pembrolizumab for liver metastatic colorectal cancer who have progressed on at least two lines of chemotherapy

jitc · abstract · 2025-11-04 · 3 matching annotations

94.2%

UC Irvine Medical Center China Medical University Triservice General Hospital pembrolizumab Colorectal cancer pembro mCRC-MSS Teclison, Inc.

…Median age 56, and range 31-80) were enrolled in 2 sites (22 in UC Irvine Medical Center, 7 in China Medical University, Hsinchu Hospital in Taiwan). Al…

501 A first in human phase 0 microdose study with the novel anti-ROR1 antibody (PBA-0405) in patients with solid tumors of soft tissue sarcoma and head and neck cancer

jitc · abstract · 2025-11-04 · 3 matching annotations

94.3%

University of Pennsylvania Presage Biosciences WCG PBA-0405 Soft Tissue Sarcoma Head and Neck squamous cell carcinoma HNSCC STS

…is study was approved by the Institutional Review Boards of the University of Pennsylvania (approval #855699), and WCG (approval #20240440). All patients …

515 Tumor agnostic spatially defined immune cell gene signatures predict immunotherapy outcomes

jitc · abstract · 2025-11-04 · 3 matching annotations

89.1%

Yale University Yale Human Investigation Committee melanoma NSCLC head and neck squamous cell carcinoma triple-negative breast cancer non-small cell lung cancer HNSCC TNBC ICIs

…was obtained from the Yale Human Investigations Committee (HIC; Yale University, New Haven, CT; HIC no. 1409014537)Abstract 515 Figure 1Cluster…

51 Targeted anti-idiotype antibody discovery through functional pre-selection and de novo sequencing

jitc · abstract · 2025-11-04 · 3 matching annotations

91.3%

Illumina MiSeq Orbitrap Exploris 240 adalimumab Orbitrap Exploris 240

…oosters. RNA from splenocytes was used for BCR sequencing on an Illumina MiSeq. LC-MS/MS was performed on an Orbitrap Exploris 240 using HCD…

534 A Phase 1 dose-escalation and expansion study evaluating the safety, efficacy, and pharmacokinetics of EVOLVE104 in subjects with advanced urothelial and squamous cell carcinomas

jitc · abstract · 2025-11-04 · 3 matching annotations

86.4%

Cohort B Cohort A EVOLVE104 EIU-104101 urothelial carcinoma squamous cell carcinomas FDA EVOLVE TCEs transitional cell carcinomas of the urinary tract locally advanced or metastatic solid tumors

…1:1 to two doses to determine the recommended phase 2 dose; and Cohort B, which will enroll up to 40 subjects in relevant indications ot…

535 EVEREST-2: a phase 1/2 study of A2B694, a logic-gated Tmod CAR T therapy to treat solid tumors expressing mesothelin (MSLN) with HLA-A*02 loss of heterozygosity: initial safety and efficacy results

jitc · abstract · 2025-11-04 · 3 matching annotations

79.3%

A2 Bio BASECAMP-1 A2B694 NSCLC pembrolizumab dexamethasone carboplatin

…ses, data managers, and apheresis teams at each study site; and A2 Bio. Medical writing support was provided by Jennifer M. Kulak, PhD…

540 Phase I trial of DOC1021 cell-based immunotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma

jitc · abstract · 2025-11-04 · 3 matching annotations

93.7%

Baylor College of Medicine WCG institutional review board DOC1021 Pancreatic ductal adenocarcinoma (PDAC)DOC1021-related peg-IFN Food and Drug Administration Cancer Cures 4 Kids Diakonos Oncology Corporation

…m the WCG institutional review board (reference #20192574), the Baylor College of Medicine institutional review board, an independent data safety monitori…

547 A phase 1b study of intraperitoneal cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in platinum resistant ovarian cancer

jitc · abstract · 2025-11-04 · 3 matching annotations

94.8%

Dana-Farber Cancer Institute Dana-Farber/Harvard Cancer Center Biol Blood Marrow Transplant ECOG Performance Status PHASE ONE Foundation IL-12 myeloid leukemia IL-15 IL-18 PROC+6 more

…ents.Conclusions This study continues to enroll patients at the Dana-Farber Cancer Institute ( NCT06321484).Acknowledgements Product manufacturing performed…

585 DENALI-1: a seamless phase 1/2 study of A2B395, a logic-gated, allogeneic, Tmod CAR T therapy, in patients with EGFR-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity

jitc · abstract · 2025-11-04 · 3 matching annotations

80.9%

A2 Bio BASECAMP-1 A2B395 solid tumors A2B530 hematologic malignancies graft-vs-host disease

…ses, data managers, and apheresis teams at each study site; and A2 Bio. Medical writing support was provided by Jennifer M. Kulak, PhD…